Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,4-galactosyltransferase 1 (B4GALT1) is a glycosyltransferase enzyme that catalyzes the transfer of galactose from UDP-galactose to N-acetylglucosamine (GlcNAc) residues on glycoproteins and glycolipids, forming a β(1→4) linkage. It plays a crucial role in the biosynthesis of complex glycoconjugates and is essential for proper protein glycosylation, which is critical for various cellular processes, including cell-cell recognition, signaling, and immune response. In lactating mammary glands, it forms a heterodimer with α-lactalbumin to synthesize lactose. Defects in B4GALT1 can cause congenital disorder of glycosylation type II D (CDG2D), leading to multisystemic symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,4-galactosyltransferase 1 (B4GALT1).